Olfactory Dysfunction in -Thalassemia Major Patients Treated with Iron-Chelating Agents

Basit Öğe Kaydı
dc.contributor.authorDerin, Serhan
dc.contributor.authorErdogan, Selvet
dc.contributor.authorSahan, Murat
dc.contributor.authorAzik, Mehmet Fatih
dc.contributor.authorDerin, Hatice
dc.contributor.authorTopal, Yasar
dc.contributor.authorTopal, Hatice
dc.date.accessioned2024-02-23T14:26:56Z
dc.date.available2024-02-23T14:26:56Z
dc.date.issued2017
dc.departmentNEÜen_US
dc.description.abstractOcular and ophthalmologic adverse effects may occur in patients with -thalassemia major (BTM) treated regularly with blood transfusions and iron-chelating agents. We hypothesized that olfactory dysfunction may be present in this patient population. We aimed to investigate olfactory dysfunction in patients with BTM and to determine etiologic factors. A total of 43 patients with BTM were included in the study. Forty-three subjects without nasal complaints, history of facial trauma, or nasal surgery were included as the controls. All participants had nasal endoscopy. The use of iron-chelating agents by patients with BTM and their duration of use were recorded, as well as hemoglobin and ferritin levels. The Sniffin Sticks test (SST) was used to assess olfactory function, comparing results between the BTM and control groups. The correlations of SST scores with the other study parameters were analyzed. Eight (18.6%) of 43 patients in the BTM group and none of the subjects in the control group had hyposmia (p < 0.001). Older age, low hemoglobin level, and longer use of deferoxamine were found to be correlated with olfactory dysfunction. Olfactory dysfunction can occur in patients with BTM treated with iron-chelating agents. The results suggest that screening for olfactory function should be part of the routine follow-up of patients with BTM.en_US
dc.identifier.doi10.1177/0145561317096010-1103
dc.identifier.endpageE12en_US
dc.identifier.issn0145-5613
dc.identifier.issn1942-7522
dc.identifier.issue10.Kasen_US
dc.identifier.pmid29121379en_US
dc.identifier.scopus2-s2.0-85032942224en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpageE8en_US
dc.identifier.urihttps://doi.org/10.1177/0145561317096010-1103
dc.identifier.urihttps://hdl.handle.net/20.500.12452/14375
dc.identifier.volume96en_US
dc.identifier.wosWOS:000471966300003en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSage Publications Incen_US
dc.relation.ispartofEnt-Ear Nose & Throat Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subject[Keyword Not Available]en_US
dc.titleOlfactory Dysfunction in -Thalassemia Major Patients Treated with Iron-Chelating Agentsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu